MX2022015899A - Metodo para determinar antigeno libre de un anticuerpo en una muestra. - Google Patents

Metodo para determinar antigeno libre de un anticuerpo en una muestra.

Info

Publication number
MX2022015899A
MX2022015899A MX2022015899A MX2022015899A MX2022015899A MX 2022015899 A MX2022015899 A MX 2022015899A MX 2022015899 A MX2022015899 A MX 2022015899A MX 2022015899 A MX2022015899 A MX 2022015899A MX 2022015899 A MX2022015899 A MX 2022015899A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
determining
tracer
epitope
Prior art date
Application number
MX2022015899A
Other languages
English (en)
Inventor
Gregor Jordan
Martin Schaefer
Maria Viert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022015899A publication Critical patent/MX2022015899A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Abstract

En el presente documento se informa un método para determinar el antígeno libre de un anticuerpo en una muestra de suero sin diluir que comprende las etapas de: a) aplicar la muestra sin diluir a una fase sólida en la que se ha inmovilizado un anticuerpo de captura para formar un complejo de anticuerpo de captura-antígeno, en donde el anticuerpo de captura compite con el anticuerpo por unirse a un primer epítopo en el antígeno, b) aplicar a la fase sólida un anticuerpo trazador para formar un complejo de anticuerpo de captura-antígeno-anticuerpo trazador, en donde el anticuerpo trazador se une específicamente a un segundo epítopo en el antígeno, en donde el epítopo del anticuerpo trazador no se superpone con el epítopo del anticuerpo de captura sobre el antígeno, y c) determinar el antígeno libre del anticuerpo por medio de la determinación del anticuerpo trazador en el complejo de anticuerpo de captura-antígeno-anticuer po trazador.
MX2022015899A 2020-06-16 2021-06-14 Metodo para determinar antigeno libre de un anticuerpo en una muestra. MX2022015899A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20180205 2020-06-16
PCT/EP2021/065880 WO2021254926A1 (en) 2020-06-16 2021-06-14 Method for determining the free antigen of an antibody in a sample

Publications (1)

Publication Number Publication Date
MX2022015899A true MX2022015899A (es) 2023-01-24

Family

ID=71103268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015899A MX2022015899A (es) 2020-06-16 2021-06-14 Metodo para determinar antigeno libre de un anticuerpo en una muestra.

Country Status (11)

Country Link
US (1) US20230393125A1 (es)
EP (1) EP4165409A1 (es)
JP (1) JP2023530977A (es)
KR (1) KR20230017308A (es)
CN (1) CN115917320A (es)
AU (1) AU2021294222A1 (es)
BR (1) BR112022025675A2 (es)
CA (1) CA3183441A1 (es)
IL (1) IL298923A (es)
MX (1) MX2022015899A (es)
WO (1) WO2021254926A1 (es)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Luminescence test method and device based on magnetic tiny particles, containing many magnets
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2002216314A1 (en) 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
FR2842069B1 (fr) 2002-07-12 2004-09-10 Pellenc Sa Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne
US20050148975A1 (en) 2003-12-31 2005-07-07 Kimberly-Clark Worldwide, Inc. Disposable garment having an elastic inner layer with a narrow width in the crotch region
WO2007096586A1 (en) 2006-02-20 2007-08-30 Pepperl & Fuchs (De) Fieldbus physical layer diagnostics data conversion device
WO2008060790A2 (en) 2006-10-13 2008-05-22 Ochsner Clinic Foundation Detection of ckd or cad using bmp-4
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EA027575B1 (ru) 2008-08-05 2017-08-31 Новартис Аг Антитело или его антигенсвязывающий фрагмент, связывающий человеческий белок с5, содержащая их композиция, нуклеиновая кислота, кодирующая антитело или его антигенсвязывающий фрагмент, содержащие эту кислоту вектор и клетка-хозяин и применение антитела или его антигенсвязывающего фрагмента
EP2894165B1 (en) 2008-11-10 2023-01-04 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN104541168B (zh) 2012-08-08 2017-04-26 弗·哈夫曼-拉罗切有限公司 基于免疫测定法的溶液中结合动力学的测定
EP3122461B1 (en) 2014-03-28 2019-12-18 Curiosity Diagnostics Sp. z o.o. Device for simultaneous and uniform thermal cycling of samples and uses thereof
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample

Also Published As

Publication number Publication date
KR20230017308A (ko) 2023-02-03
US20230393125A1 (en) 2023-12-07
WO2021254926A1 (en) 2021-12-23
BR112022025675A2 (pt) 2023-03-07
IL298923A (en) 2023-02-01
EP4165409A1 (en) 2023-04-19
CA3183441A1 (en) 2021-12-23
JP2023530977A (ja) 2023-07-20
AU2021294222A1 (en) 2023-01-19
CN115917320A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
ATE236398T1 (de) Verbessertes verfahren zum nachweis von säure- resistenten bakterien der gattung helicobacter im stuhl
ES431413A1 (es) Metodo para detectar en muestras de plasma o suero sangui- neo la presencia de proteinas capaces de actuar como antige-nos o anticuerpos.
HK1078647A1 (en) Analytical sandwich test for determining nt-probnp
RU2016107435A (ru) Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
RU2014128510A (ru) Способ определения свободного связывающего партнера мультиспецифичного связующего
JP2007525427A5 (es)
RU2008139098A (ru) Способы диагностики рака поджелудочной железы с применением белка reg4
RU2014133701A (ru) Способ детекции партнера по связыванию мультиспецифического связывающего агента
JP2019015737A5 (es)
JP2019015736A5 (es)
JP2015502547A5 (es)
RU2013129203A (ru) Моноклональное антитело, распознающее белок l2 папилломавируса человека (впч), и способ определения титра впч-нейтрализующего антитела, использующий такое антитело
Kobayashi et al. Noncompetitive immunoassays for small molecules with high sensitivity and specificity
EP0310132A3 (en) Immunoassay utilizing igg capture antibody and multiple monoclonal antibody detection system
KR970707157A (ko) 항체의 특정 클래스에 특이적인 간섭 억제 시약(interference-suppressing reagent specific to certain classes of antibodies)
MX2022015899A (es) Metodo para determinar antigeno libre de un anticuerpo en una muestra.
NO20052870L (no) Immunoanalysemetode og sett for anvendelse derav
RU2019132201A (ru) Антитела к человеческому эритроферрону и их применение
WO2021217140A3 (en) Specificity enhancing reagents for covid-19 antibody testing
JPS57208458A (en) Labeled antibody for immunochemical measurement
GB2596993A (en) Antibodies to symmetrically dimethylated arginine analytes and use thereof
RU2015140955A (ru) Специфическое определение крысиных антител в сыворотке мышей
TH2001004675A (th) โมโนโคลนอลแอนติบอดีและตัวยับยั้งปฏิกิริยาที่ไม่จำเพาะ
Manouvriez Use of anti-rat kappa light chain allotype monoclonal antibodies for the quantification of rat monoclonal antibodies in ascitic fluid or serum
WO2023196745A3 (en) Human ige monoclonal antibodies to parasitic worm antigens and uses therefor